MannKind Engages Locust Walk to Explore Strategic Options for MannKind’s Non-insulin Technosphere-based Pipeline Candidates

VALENCIA, Calif., June 05, 2017 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD), focused on the discovery, development and commercialization of therapeutic products, announces its decision to explore strategic and financial alternatives for MannKind’s novel Technosphere-based pipeline candidates. This Technosphere platform is characterized by an ultra-rapid onset of action, simple and needle-free administration, avoidance of hepatic metabolism, and improved bioavailability. Continuing MannKind’s strong desire to help patients, Locust Walk will seek strategic partners and investors to non-dilutively advance the development of Technosphere-based therapies which demonstrate benefit across a variety of treatment areas, including but not limited to hypertension, anaphylactic shock, nausea, respiratory disease and pain.

“MannKind has focused its financial resources on the commercialization of Afrezza and is seeking alternate means to fund our other development programs for the Technosphere platform.  I am excited to collaborate with Locust Walk, who has extensive global experience in pharmaceutical partnering, to help bring our product candidates to market, such as Epinephrine Technosphere® for anaphylaxis, Trepostinil Technosphere® for pulmonary arterial hypertension, and Palonosetron Technosphere® for chemotherapy-induced nausea and vomiting,” said Raymond Urbanski, Chief Medical Officer of MannKind Corporation.

About MannKind Corporation

MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes.  MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding MannKind’s intention to out-license potential pharmaceutical products.  Words such as “believes”, “anticipates”, “plans”, “expects”, “intend”, “will”, “goal”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the MannKind’s current expectations.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the ability to obtain regulatory approvals, the availability of satisfactory deal terms and other risks detailed in MannKind’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2016 and subsequent periodic reports on Form 10-Q and current reports on Form 8-K.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

CONTACT: Company Contact:
Rose Alinaya
Acting CFO
661-775-5300
ralinaya@mannkindcorp.com